Zacks Research Has Negative Outlook of IOVA FY2026 Earnings
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) – Analysts at Zacks Research cut their FY2026 earnings per share estimates for shares of Iovance Biotherapeutics in a research note issued on Friday, June 26th. Zacks Research analyst Team now anticipates that the biotechnology company will earn ($0.72) per share for the year, down from their previous […]
30 Jun 07:43 · The Cerbat Gem